Next Article in Journal
Venous Thromboembolic Risk Does Not Increase After a Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine in Cancer Patients Receiving Active Systemic Therapies: Updated Results from the Vax-On-Third-Profile Study
Previous Article in Journal
Vaccination Against RhoC in Prostate Cancer Patients Induces Potent and Long-Lasting CD4+ T Cell Responses with Cytolytic Potential in the Absence of Clinical Efficacy: A Randomized Phase II Trial
Previous Article in Special Issue
Lipoprotein Signal Peptide as Adjuvants: Leveraging Lipobox-Driven TLR2 Activation in Modern Vaccine Design
 
 
Review

Article Versions Notes

Vaccines 2025, 13(4), 391; https://doi.org/10.3390/vaccines13040391
Action Date Notes Link
article xml file uploaded 7 April 2025 12:07 CEST Original file -
article xml uploaded. 7 April 2025 12:07 CEST Update -
article pdf uploaded. 7 April 2025 12:07 CEST Version of Record https://www.mdpi.com/2076-393X/13/4/391/pdf-vor
article supplementary file uploaded. 7 April 2025 12:07 CEST - https://www.mdpi.com/2076-393X/13/4/391#supplementary
article html file updated 7 April 2025 12:08 CEST Original file -
article xml file uploaded 8 April 2025 06:10 CEST Update -
article xml uploaded. 8 April 2025 06:11 CEST Update -
article pdf uploaded. 8 April 2025 06:11 CEST Updated version of record https://www.mdpi.com/2076-393X/13/4/391/pdf-vor
article html file updated 8 April 2025 06:11 CEST Update -
article xml file uploaded 8 April 2025 08:35 CEST Update -
article xml uploaded. 8 April 2025 08:35 CEST Update https://www.mdpi.com/2076-393X/13/4/391/xml
article pdf uploaded. 8 April 2025 08:35 CEST Updated version of record https://www.mdpi.com/2076-393X/13/4/391/pdf
article html file updated 8 April 2025 08:37 CEST Update https://www.mdpi.com/2076-393X/13/4/391/html
Back to TopTop